Literature DB >> 12689408

Roundtable report: importance of antiretroviral drug concentrations in sanctuary sites and viral reservoirs.

Y Sunila Reddy1, Angela Kashuba, John Gerber, Veronica Miller.   

Abstract

Mesh：

Substances：

Year:  2003        PMID： 12689408     DOI： 10.1089/088922203763315669

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN： 0889-2229            Impact factor:   2.205


× No keyword cloud information.
  12 in total

1.  The male genital tract is not a pharmacological sanctuary from efavirenz.

Authors:  L B Avery; R P Bakshi; Y J Cao; C W Hendrix
Journal:  Clin Pharmacol Ther       Date:  2011-06-01       Impact factor: 6.875

2.  Efavirenz concentrations in CSF exceed IC50 for wild-type HIV.

Authors:  Brookie M Best; Peter P Koopmans; Scott L Letendre; Edmund V Capparelli; Steven S Rossi; David B Clifford; Ann C Collier; Benjamin B Gelman; Gilbert Mbeo; J Allen McCutchan; David M Simpson; Richard Haubrich; Ronald Ellis; Igor Grant
Journal:  J Antimicrob Chemother       Date:  2010-11-23       Impact factor: 5.790

3.  Low cerebrospinal fluid concentrations of the nucleotide HIV reverse transcriptase inhibitor, tenofovir.

Authors:  Brookie M Best; Scott L Letendre; Peter Koopmans; Steven S Rossi; David B Clifford; Ann C Collier; Benjamin B Gelman; Christina M Marra; Justin C McArthur; J Allen McCutchan; Susan Morgello; David M Simpson; Edmund V Capparelli; Ronald J Ellis; Igor Grant
Journal:  J Acquir Immune Defic Syndr       Date:  2012-04-01       Impact factor: 3.731

Review 4.  HIV evolution and escape.

Authors:  Douglas D Richman; Susan J Little; Davey M Smith; Terri Wrin; Christos Petropoulos; Joseph K Wong
Journal:  Trans Am Clin Climatol Assoc       Date:  2004

5.  High concentration of raltegravir in semen of HIV-infected men: results from a substudy of the EASIER-ANRS 138 trial.

Authors:  Caroline Barau; Constance Delaugerre; Joséphine Braun; Nathalie de Castro; Valérie Furlan; Isabelle Charreau; Laurence Gérard; Caroline Lascoux-Combe; Jean-Michel Molina; Anne-Marie Taburet
Journal:  Antimicrob Agents Chemother       Date:  2009-12-07       Impact factor: 5.191

6.  Darunavir, ritonavir, and etravirine pharmacokinetics in the cervicovaginal fluid and blood plasma of HIV-infected women.

Authors:  Kristine Patterson; Steven Jennings; Ron Falcon; Joseph Mrus; Angela Kashuba
Journal:  Antimicrob Agents Chemother       Date:  2010-12-20       Impact factor: 5.191

7.  Population pharmacokinetics of abacavir in plasma and cerebrospinal fluid.

Authors:  Edmund V Capparelli; Scott L Letendre; Ronald J Ellis; Parul Patel; Diane Holland; J Allen McCutchan
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

8.  Low atazanavir concentrations in cerebrospinal fluid.

Authors:  Brookie M Best; Scott L Letendre; Eileen Brigid; David B Clifford; Ann C Collier; Benjamin B Gelman; Justin C McArthur; J Allen McCutchan; David M Simpson; Ronald Ellis; Edmund V Capparelli; Igor Grant
Journal:  AIDS       Date:  2009-01-02       Impact factor: 4.177

9.  Cognitive functioning during highly active antiretroviral therapy interruption in human immunodeficiency virus type 1 infection.

Authors:  Meredith E Childers; Steven Paul Woods; Scott Letendre; J Allen McCutchan; Debralee Rosario; Igor Grant; Monica Rivera Mindt; Ronald J Ellis
Journal:  J Neurovirol       Date:  2008-11       Impact factor: 2.643

10.  Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative women.

Authors:  Julie B Dumond; Kristine B Patterson; Allison L Pecha; Rebecca E Werner; Emma Andrews; Bharat Damle; Randall Tressler; Jochen Worsley; Angela D M Kashuba
Journal:  J Acquir Immune Defic Syndr       Date:  2009-08-15       Impact factor: 3.731
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.